PNMA1

Across TCGA pan-cancer cohorts, PNMA1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PNMA1 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PNMA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PNMA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where PNMA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.991	0.504	.001	30	view →
UCEC	OS	Median	All	0.847	0.984	.009	12	view →
LUAD	DFS	Quartile	III,IV	0.834	0.440	.026	3	view →
GBM	OS	Tertile	All	0.553	0.307	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PNMA1–PDAC (DFS)

Open the PDAC breakdown →